Ahmed Nagy*, Omar Abdel Rahman, Heba Abdullah and Ahmed Negida Pages 50 - 55 ( 6 )
Background: Although well established for the effective management of hematologic cancers, maintenance chemotherapy has only been recently incorportated as a treatment paradigm for advanced non–small-cell lung cancer. Maintenance chemotherapy aims to prolong a clinically favorable response state achieved after finishing induction therapy which is usually predefined in number before startng treatment. There are 2 modalities for maintenance therapy; continuation maintenance (involving a non-platinum component which was a part of the induction protocol or a targeted agent) and switch maintenance therapy (utilizing a new agent which was not a part of the induction regimen).
Methods: The purpose of this article is to review the role of maintenance therapy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC) and provide a brief overview about induction chemotherapy in NSCLC to address the basis of maintenance therapy as a treatment option. We will also compare the impact of maintenance chemotherapy with the now evolving role of immunotherapy in NSCLC.
Results: There have been 4 maintenance studies to date showing prolonged PFS and OS with statistical significance. However, Three out of the four studies (ECOG4599, JMEN, and PARAMOUNT) did not report tumor molecular analysis. As regard Immunotherapy, current data is in favour of strongly an increasing role for immunotherapy in NSCLC.
Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.
Chemotherapy, NSCLC, targeted therapy, lung cancer, overall survival, anticancer agents.
Department of Clinical Oncology and Nuclear Medicine, Ain Shams University, Cairo, Department of Clinical Oncology and Nuclear Medicine, Ain Shams University, Cairo, Department of Clinical Oncology, Mit Ghamr Cancer Center, Mit Al Faramawi, Mit Ghamr, Faculty of Medicine, Agazig University, Cairo